Clinical Trial Update: Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This entry describes an ongoing Phase 1 clinical trial evaluating tazemetostat in combination with topotecan and pembrolizumab for recurrent small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Cancer
• Limited-stage Small Cell Cancer
• Platinum-resistant Small Cell Cancer
• Platinum-sensitive Small Cell Cancer
• Small Cell Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tazemetostat (tazemetostat)
• Topotecan (topotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING